OBJECTIVE: To validate accelerometry based on its correlations with 6-minute walk distance (6MWD) and oxygen cost of walking as objective markers of walking limitations in multiple sclerosis (MS). DESIGN: Cross-sectional. SETTING: Laboratory and general community. PARTICIPANTS: Ambulatory participants with MS (N=26) who resided in the local community. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Patient Determined Disease Steps (PDDS) scale and Multiple Sclerosis Walking Scale-12 (MSWS-12); 6-minute walk test while wearing a portable metabolic unit for measuring the 6MWD and oxygen cost of walking; accelerometer during the waking hours of a 7-day period. RESULTS: The average of total daily movement counts from the accelerometer correlated significantly and strongly with MSWS-12 scores (ρ=-.681, P=.001), PDDS scores (ρ=-.609, P=.001), 6MWD (ρ=.519, P=.003), and oxygen cost of walking (ρ=-.541, P=.002). CONCLUSIONS: We provide evidence that further supports the validity of accelerometry as a measure of walking limitations in ambulatory persons with MS.
OBJECTIVE: To validate accelerometry based on its correlations with 6-minute walk distance (6MWD) and oxygen cost of walking as objective markers of walking limitations in multiple sclerosis (MS). DESIGN: Cross-sectional. SETTING: Laboratory and general community. PARTICIPANTS: Ambulatory participants with MS (N=26) who resided in the local community. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Patient Determined Disease Steps (PDDS) scale and Multiple Sclerosis Walking Scale-12 (MSWS-12); 6-minute walk test while wearing a portable metabolic unit for measuring the 6MWD and oxygen cost of walking; accelerometer during the waking hours of a 7-day period. RESULTS: The average of total daily movement counts from the accelerometer correlated significantly and strongly with MSWS-12 scores (ρ=-.681, P=.001), PDDS scores (ρ=-.609, P=.001), 6MWD (ρ=.519, P=.003), and oxygen cost of walking (ρ=-.541, P=.002). CONCLUSIONS: We provide evidence that further supports the validity of accelerometry as a measure of walking limitations in ambulatory persons with MS.
Authors: Núria Sola-Valls; Yolanda Blanco; Maria Sepúlveda; Sara Llufriu; Elena H Martínez-Lapiscina; Delon La Puma; Francesc Graus; Pablo Villoslada; Albert Saiz Journal: J Neurol Date: 2015-05-10 Impact factor: 4.849
Authors: V J Block; A Lizée; E Crabtree-Hartman; C J Bevan; J S Graves; R Bove; A J Green; B Nourbakhsh; M Tremblay; P-A Gourraud; M Y Ng; M J Pletcher; J E Olgin; G M Marcus; D D Allen; B A C Cree; J M Gelfand Journal: J Neurol Date: 2016-11-28 Impact factor: 4.849